Brief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
15/05/2026 21:22
May 15 (Reuters) - Candel Therapeutics Inc CADL.O: CANDEL THERAPEUTICS REPORTS EXTENDED CLINICAL BENEFIT OVER MULTIPLE CLINICAL ENDPOINTS IN PATIENTS FROM PHASE 3 TRIAL OF AGLATIMAGENE BESADENOVEC (CAN-2409) IN LOCALIZED PROSTATE CANCER UNDER PROLONGED FOLLOW-UP AT AUA 2026 ANNUAL MEETING Source text: ID:nGNX89XTBc Further company coverage: CADL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec